Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Therapeutic Discovery

Modulation of 4E-BP1 Function as a Critical Determinant of Enzastaurin-Induced Apoptosis

Chad A. Dumstorf, Bruce W. Konicek, Ann M. McNulty, Stephen H. Parsons, Luc Furic, Nahum Sonenberg and Jeremy R. Graff
Chad A. Dumstorf
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruce W. Konicek
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ann M. McNulty
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen H. Parsons
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luc Furic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nahum Sonenberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremy R. Graff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-10-0413 Published December 2010
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Enzastaurin suppresses cell signaling downstream of the AKT/mTOR pathway. Cancer cells were incubated with 0 to 4μmol/L enzastaurin in media supplemented with 1% HI FBS for 16 and 24 hours. Western blot analyses were done for total 4E-BP1, 4E-BP1Thr37/46, 4E-BP1Ser65, 4E-BP1Thr70, AKTSer473, AKTThr308, mTOR, mTORSer2448, p70S6KThr389, rpS6Ser240/244, rpS6, AKT, and β-actin. A, HCT116 colon cancer cells; B, CRL2611 glioblastoma cells; C, Farage B-cell lymphoma cells.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Enzastaurin decreases eIF4F complex levels. Cancer cells were incubated with 0 to 4 μmol/L enzastaurin in media supplemented with 1% HI FBS for 24 hours. Western blot analyses were done for total eIF4G, eIF4E, and 4E-BP1 from m7GTP pull-down lysates and whole cell lysates. Whole lysates were additionally probed for β-actin to control for loading and transfer. Graph represents eIF4G normalized to eIF4E divided by 4E-BP1 normalized to eIF4E [(eIF4G/eIF4E)/(4E-BP1/eIF4E)]. Data represent the mean of 3 separate experiments (±SEM). A, HCT116 colon cancer cells; B, Farage B-cell lymphoma cells; C, CRL2611 glioblastoma cells; D, percentage of apoptotic cells following enzastaurin treatment in HCT116 cells and in HCT116 colon cancer cells selected for reduced sensitivity (HCT116res) to enzastaurin as measured by TUNEL staining. Inset shows the levels of eIF4E and 4E-BP1 by Western blot from whole cell lysates. β-Actin was assessed to control for loading and transfer.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    4E-BP1 depletion reduces enzastaurin-induced apoptosis. A, Western blot analyses for total 4E-BP1 and β-actin 72 hours after 4E-BP1 siRNA transfection in HCT116 colon cancer cells and CRL2611 glioblastoma cells. Apoptosis after 72 hours 4E-BP1 siRNA treatment followed by incubation with 0 to 2 μmol/L enzastaurin in media supplemented with 1% HI FBS for 48 hours HCT116 (B) or 72 hours CRL2611 (C). Apoptosis was determined using the Cell Death Detection ELISA (Roche Applied Science). Graph represents mean (±SEM); *, P < 0.05 by unpaired t test.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    4E-BP1/2 knockout increases eIF4F complex levels and reduces enzastaurin-induced apoptosis. Wild-type (WT) and 4E-BP1/2 knockout (KO) murine embryonic fibroblasts were incubated with 1 to 2 μmol/L enzastaurin in media supplemented with 1% HI FBS. A, apoptosis was determined 72 hours after enzastaurin treatment using the Cell Death Detection ELISA (Roche Applied Science). Graph represents mean (±SEM); *, P < 0.05 by unpaired t test. B, Western blot analyses from m7GTP pull-down lysates were done for total eIF4E and 4E-BP1 after 24 hours enzastaurin treatment. C, graph represents eIF4G normalized to eIF4E divided by 4E-BP1 normalized to eIF4E [(eIF4G/eIF4E)/(4E-BP1/eIF4E)]. Data represent mean of 3 separate experiments (±SEM).

PreviousNext
Back to top
Molecular Cancer Therapeutics: 9 (12)
December 2010
Volume 9, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Modulation of 4E-BP1 Function as a Critical Determinant of Enzastaurin-Induced Apoptosis
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Modulation of 4E-BP1 Function as a Critical Determinant of Enzastaurin-Induced Apoptosis
Chad A. Dumstorf, Bruce W. Konicek, Ann M. McNulty, Stephen H. Parsons, Luc Furic, Nahum Sonenberg and Jeremy R. Graff
Mol Cancer Ther December 1 2010 (9) (12) 3158-3163; DOI: 10.1158/1535-7163.MCT-10-0413

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Modulation of 4E-BP1 Function as a Critical Determinant of Enzastaurin-Induced Apoptosis
Chad A. Dumstorf, Bruce W. Konicek, Ann M. McNulty, Stephen H. Parsons, Luc Furic, Nahum Sonenberg and Jeremy R. Graff
Mol Cancer Ther December 1 2010 (9) (12) 3158-3163; DOI: 10.1158/1535-7163.MCT-10-0413
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Material and Methods
    • Results and Discussion
    • Disclosure of Potential Conflicts of Interest
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Glucocorticoid Receptor Signals in Bladder Cancer Cells
  • Ligand Systemic Targeting of the Grp78 Promoter
  • Sorafenib Targets VCP in Hepatocellular Cancer Cells
Show more Therapeutic Discovery
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement